Sanofi, Regeneron plot Dupixent filing in young eczema patients, advancing drug's megablockbuster ambitions

Sanofi and Regeneron’s Dupixent is already approved to treat eczema in kids as young as 6 years old—and it’s well on its way to becoming a $10 billion drug. Armed with a trial win in even younger children and infants, the antibody med could soon get another boost.